This application claims priority to U.S. patent application Ser. No. 10/728,728 filed Dec. 5, 2003 entitled Expandable Percutaneous Sheath, which is hereby incorporated herein by reference in its entirety.
Field of the Invention
The present invention relates to medical devices and, more particularly, to methods and devices for forming a percutaneous channel. In one application, the present invention relates to methods and devices for providing percutaneous access to a soft tissue or organ.
Description of the Related Art
A wide variety of diagnostic or therapeutic procedures involve the introduction of a device through a natural or artificially created access pathway. A general objective of access systems, which have been developed for this purpose, is to minimize the cross-sectional area of the puncture, while maximizing the available space for the diagnostic or therapeutic instrument. These procedures include, among others, a wide variety of laprascopic diagnostic and therapeutic interventional procedures.
Percutaneous nephrostomy is an example of one type of therapeutic interventional procedure that requires an artificially created pathway. Percutaneous nephrostomy is a minimally invasive procedure that can be used to provide percutaneous access to the upper urinary tract. At first, percutaneous nephrostomy was used only for urinary diversion but now it may be used for more complex procedures such as stone extraction, integrate endopyelotomy, and resection of transitional cell carcinoma of the upper urinary tract.
In many percutaneous nephrostomy systems, a stiff guidewire is first placed into the renal collection system through the renal parenchyma and the ureter using fluoroscopic control. A second “safety wire” may be placed with a dual lumen catheter for maintaining the tract should the first wire become dislodged or kinked.
Once guidewire control is established, a dilator sheath is used to create the tract and establish a rigid working lumen. An early technique involved advancing a flexible, 8 French, tapered catheter over the first guidewire to provide guidewire protection as well as a stable path for the placement of larger diameter dilators and sheaths. The larger diameter sheaths are sequentially advanced over the catheter and each other until an approximately 34 French tract is established. The inner sheaths or dilators may then be sequentially removed such that the outermost sheath defines a working lumen. In this system, tract formation is accomplished by the angular shearing force of each subsequent sheath placement, which cuts a path through the tissue. Because axial pressure is required to advance and place each sheath, care must be taken to avoid kinking the tapered catheter and/or advancing the sheaths to far and perforating the renal pelvis. This technique also requires a large number of steps.
A more recent technique utilizes a balloon that is advanced over the first guide wire. Once in place in the renal pelvis, the balloon is inflated with a dilute contrast media solution to enlarge the tract. Once the balloon is inflated to a suitable diameter, a rigid sheath is advanced over the balloon. Advancing the rigid sheath over the balloon typically requires applying axial force to the sheath and rotation. The balloon may then be deflated and removed from the rigid sheath so that the rigid sheath may define a working lumen. In general, this technique is considered less traumatic than the previously described technique. Nevertheless, placement of the rigid sheath still involves angular shearing forces and several steps.
Additional information regarding percutaneous nephrostomy can be found in McDougall, E. M., et al. (2002), Percutaneous Approaches to the Upper Urinary Tract, Campbell's Urology. 8th ed, vol. 4, pp. 3320-3357, Chapter 98. Philadelphia, Saunders.
A need therefore remains for improved access technology which allows a device to be percutaneously passed through a small diameter tissue tract, while accommodating the introduction of relatively large diameter instruments.
A percutaneous access sheath is provided according to an embodiment of the present invention. In one application, the percutaneous access sheath is used to provide access to the upper urinary tract or bladder.
In one embodiment, the percutaneous access sheath may be used in conjunction with a deployment catheter, which may be provided with a balloon at its distal end. The percutaneous access sheath has a proximal section and a variable diameter distal section. The deployment catheter may be disposed within the percutaneous access sheath such that the balloon is positioned within the distal section of the percutaneous access sheath.
In one embodiment, the distal section of the percutaneous access sheath is restrained in a first, small diameter by a releasable restraint such as a perforated, scored or thin wall continuos film insert jacket. The distal section of the percutaneous access sheath is creased by at least 2 to 4 or 2 to 6 folds and inserted into a distal section of the jacket. This gives the percutaneous access sheath a smaller cross-sectional profile, facilitating its insertion.
In one embodiment, the folded percutaneous access sheath is restrained within the jacket. Following insertion into a patient's anatomy, the jacket may be released by inflating the balloon on the deployment catheter. During the inflation process, the jacket separates along its longitudinal axis as the access sheath unfolds and/or expands. In one preferred embodiment, separation of the jacket during inflation, occurs along a perforated or scored line formed on the jacket. In one such embodiment, the score or perforation may be formed at or close to the distal end of the jacket such that the jacket separates at the distal end first. In another preferred embodiment, the jacket is formed from a continuous film and the separation is caused by stretching the film until it separates. After the balloon has expanded the access sheath to its full diameter and caused the jacket to separate, the jacket may be withdrawn from the patient's anatomy. In a modified embodiment, the jacket may remain coupled to the access sheath during use. The balloon may be deflated to allow the removal of the deployment catheter, leaving the percutaneous access sheath in place.
In one embodiment where the percutaneous access sheath is used to provide access to the upper urinary tract, the percutaneous access sheath may be used to provide access by tools adapted to perform biopsy, urinary diversion, stone extraction, antegrade endopyelotomy, and resection of transitional cell carcinoma and other diagnostic or therapeutic procedures of the upper urinary tract or bladder
Other applications of the percutaneous access sheath include a variety of diagnostic or therapeutic clinical situations which require access to the inside of the body, through either an artificially created or natural body lumen.
In the exemplary embodiment, the elongate tubular body 102 has a distal section 110 and a proximal section 103. The proximal section 103 has a slightly larger inner and outer diameter as compared to the distal section 110. As will be explained in more detail below, the proximal section 103 may be used to secure the access sheath 100 to a connector. With continued reference to
The length and diameter of the sheath 100 can be varied according to clinical need, as will be understood by those skilled in the art with reference to this disclosure. In one exemplary embodiment for percutaneous nephrostomy, the access sheath 100 has an overall length of about 17 to about 30 centimeters with the distal section 110 having a length of about 11 to about 24 centimeters. As will be explained in more detail below, a portion or all of the distal section 110 is expandable from a first, smaller cross-sectional profile to a second, larger cross-sectional profile. The first, smaller cross-sectional profile of the distal section 110 eases its insertion into a percutaneous treatment site. After insertion, the distal section 110 is expanded to a second, larger cross-sectional profile to provide a larger passageway for surgical instruments to reach the percutaneous treatment site. For percutaneous nephrostomy, the smaller cross-sectional profile may have a diameter of about 15 French to about 24 French and the larger cross-sectional profile may have a diameter of about 21 French to about 40 French. In the larger cross-sectional profile, the lumen 108 may have a diameter of about 18 French to about 38 French.
As mentioned above, in the illustrated embodiment, the percutaneous access sheath 100 comprises a tubing 102, which defines a lumen 108. The tubing 102 may be made of PTFE, nylon, PEBAX or polyethylene, polyurethane, silicone, or other suitable materials.
In this embodiment, the distal section 110 is creased in at least two and more preferably 2 to 6 sections, most preferably 2 to 4 sections, and collapsed from a larger to a smaller cross-sectional profile to ease its insertion. As discussed below, in one embodiment for percutaneous nephrostomy, the distal section 110 is placed into the renal collecting system through the renal parenchyma and ureters. Its length is thus determined by the anatomy and is generally in the range of about 11 cm to about 24 cm. In the illustrated embodiment, the proximal end 103 of the tubing 102 is flared and fitted onto the deployment catheter as will be explained below. The overall length of the tubing 102 depends on the distance between the insertion and treatment locations, and is generally in the range of 10-100 cm for various clinical indications. As mentioned above, for percutaneous nephrostomy, the length of the tubing is approximately 17-30 cm.
In the illustrated embodiment, the jacket 200 may be made of heat shrink PTFE. The proximal end 202 of the jacket 200 terminates at a pull tab 204, which may be formed by any of a variety of structures such as a threaded connector with a luer lock at its proximal end. The jacket 200 may be provided with a slit 206 near its proximal end 202. The jacket 200 tapers at a first tapering point 208 into a restraint section 210, which tapers again into the distal tip 212. As discussed above, the restraint section 210 restrains the distal section 110 of the percutaneous access sheath 100 in its smaller cross-sectional profile. Thus the length of the restraint section 210 is approximately the same as or slightly longer or shorter than the distal section 110, and generally falls in the range of about 1 l-25 cm.
The outside diameter of the restraint section 210 is preferably configured to ease its insertion into a percutaneous treatment site. Depending upon the clinical application, the outside diameter may be in the range of about 3 French to about 40 French. For percutaneous nephrostomy, the outside diameter may be in the range of about 5 French to about 35 French. The restraint section 210 is configured to separate and/or tear preferably along its longitudinal axis to release the access sheath 100 as it is radially expanded. In the illustrated embodiment, the jacket 200 is perforated, scored or otherwise provided with a tear line 215 from the first tapering point 208 to its distal tip 212. In another embodiment, the jacket 200 may be constructed of a material that will disrupt or separate during expansion from the first tapering point 208 to its distal tip 212. In another embodiment, the jacket 200 may be perforated, scored or otherwise provided with a tear line for only a portion of the restraint section 210. For example, in one embodiment, the restraint section 210 may be provided with a tear line at a region close to or at the distal end of the jacket 200. This may cause the jacket 200 to disrupt or separate during expansion from its distal end first
The distance between the slit 206 and the distal tip 212 is generally approximately equal to or longer than the length of the folded, compressed portion of the tubing 102 such that the folded compressed portion of the tubing 102 terminates within the restraint section 210. In one embodiment, this arrangement permits complete disruption of the jacket 200 when the access sheath 100 is fully expanded. In one embodiment, the distance between the slit 206 and the distal tip 212 is generally in the range of 6-90 cm for most clinical applications and about 11-24 cm for percutaneous nephrostomy. In the illustrated embodiment, which is configured for percutaneous nephrostomy, this distance is approximately 1 lcm, and the overall length of the jacket 200 is approximately 19 cm.
As will be explained in more detail below, in some embodiments, the jacket 200 is removed from the access sheath 100 and the surgical site after the sheath 100 is expanded. In other embodiments, the jacket 200 is attached to the sheath 100 and remains attached to the sheath 100 after it is expanded and during the surgical procedure. In such latter embodiments, the jacket 200 may be securely attached to the access sheath by, for example, at least one adhesive or heat bond, preferably extending axially along a section of the access sheath 100 generally opposite the folds or creases.
In certain embodiments a jacket 200 may not be necessary if the distal section 110 of the percutaneous access sheath 100 is made of a stretchable material that may be stretched from a first, smaller cross-sectional profile to a second, larger cross-sectional profile. In these embodiments the outer surface of the distal section 110 is preferably made of a smooth material to facilitate the insertion of the percutaneous access sheath 100 into a treatment site. In still other embodiments, the jacket 200 may be a stretchable material that may be stretched with or without elastic deformation from a first, smaller cross-sectional profile to a second, larger cross-sectional profile as the sheath is expanded.
With particular reference to
With reference back to
One exemplary embodiment of use will now be described with reference to
The guide wire 400 may be inserted into the guide wire lumen 304 (see
Following the insertion of the percutaneous access sheath assembly 150, the access sheath 100 may be expanded and released from the jacket 200. This may be accomplished by inflating, at least partially, the balloon 310 (not visible in
After the sheath 100 is released from the jacket 200, the balloon 310 may be fully inflated to expand the distal section 110 of the percutaneous access sheath to its full cross-sectional profile. See
In some embodiments, after the sheath 100 has been released from the jacket 200, the jacket 200 may be removed from the access sheath 100 and the surgical cite. In other embodiments, the jacket 200 may remain attached to the access sheath 100 during use. As explained above, in such embodiments, the jacket 200 may be securely attached to the access sheath by, for example, an adhesive or heat bond.
After the balloon 310 is inflated, it may be deflated to ease the removal of the deployment catheter 300. As discussed above, the inflation and deflation of the balloon 310 may be done via a pump connected to the port 320 of the deployment catheter 300, and preferably with a dilute contrast media being pumped, to better convey the state of the balloon.
Thus, the percutaneous access sheath 100 extends into the renal pelvis and provides a working lumen. See
It will be apparent from the disclosure herein that the percutaneous access sheath 100, the percutaneous access sheath assembly 150, and/or the methods described herein may also find utility in a wide variety of diagnostic or therapeutic procedures that require an artificially created access tract. For example, the embodiments described herein may be used in many urological applications (e.g., the removal of ureteral strictures and stones, the delivery of drugs, RF devices and radiation for cancer treatment, etc.). In such applications, the percutaneous access sheath 100 may have a length of about 30-300 cm with an unexpanded diameter of about 7-20 French and an expanded diameter of about 14-60 French. The sheath 100 may also be used in many gastrointestinal applications, which require the introduction of a surgical retractor (e.g., to the removal gallstones and appendix procedures). In such applications, the percutaneous access sheath 100 may have a length of about 10-50 cm with an unexpanded diameter of about 3-15 French and an expanded diameter of about 15-60 French. The percutaneous access sheath 100 may also be used as an access catheter for many gastrointestinal applications (e.g., colon therapies, esophageal treatment and the treatment of bowel obstructions). In such applications, the percutaneous access sheath 100 may have a length of about 30-300 cm with an unexpanded diameter of about 7-40 French and an expanded diameter of about 14-120 French.
The sheath may also be used in many cardiovascular applications (e.g., to provide access for minimally invasive heart bypass, valve replacement or the delivery of drugs or angiogenesis agents). In such applications, the percutaneous access sheath 100 may have a length of about 30-300 cm with an unexpanded diameter of about 3-12 French and an expanded diameter of about 5-30 French. For vascular applications (e.g., minimally invasive access to the aorta or contralateral leg arteries for the treatment of, for example, an abdominal aortic aneurysm), the percutaneous access sheath 100 may have a length of about 30-300 cm with an unexpanded diameter of about 5-30 French and an expanded diameter of about 15-75 French. For gynecological applications (e.g., endometrial therapies, delivery of drugs, delivery of cancer agents, sterilization procedures, etc.), the percutaneous access sheath 100 may have a length of about 10-100 cm with an unexpanded diameter of about 3-20 French and an expanded diameter of about 6-60 French.
Although the present invention has been described in terms of certain preferred embodiments, other embodiments of the invention including variations in dimensions, configuration and materials will be apparent to those of skill in the art in view of the disclosure herein. In addition, all features discussed in connection with any one embodiment herein can be readily adapted for use in other embodiments herein. The use of different terms or reference numerals for similar features in different embodiments does not imply differences other than those which may be expressly set forth. Accordingly, the present invention is intended to be described solely by reference to the appended claims, and not limited to the preferred embodiments disclosed herein.
Number | Name | Date | Kind |
---|---|---|---|
319296 | Molesworth | Jun 1885 | A |
668879 | Miller | Feb 1901 | A |
1213001 | Philips | Jan 1917 | A |
1248492 | Hill | Dec 1917 | A |
2042900 | James | Jun 1936 | A |
2548602 | Greenburg | Apr 1951 | A |
3509883 | Dibelius | May 1970 | A |
3545443 | Ansari | Dec 1970 | A |
3742958 | Rundles | Jul 1973 | A |
3789852 | Kim et al. | Feb 1974 | A |
3902492 | Greenhalgh | Sep 1975 | A |
4018230 | Ochiai et al. | Apr 1977 | A |
4141364 | Schultze | Feb 1979 | A |
4338942 | Fogarty | Jul 1982 | A |
4401433 | Luther | Aug 1983 | A |
4411655 | Schreck | Oct 1983 | A |
4451256 | Weikl et al. | May 1984 | A |
4479497 | Fogarty et al. | Oct 1984 | A |
4581025 | Timmermans | Apr 1986 | A |
4589868 | Dretler | May 1986 | A |
4601713 | Fuqua | Jul 1986 | A |
4610668 | Silvestrini et al. | Sep 1986 | A |
4636346 | Gold et al. | Jan 1987 | A |
4637396 | Cook | Jan 1987 | A |
4650466 | Luther | Mar 1987 | A |
4710181 | Fuqua | Dec 1987 | A |
4716901 | Jackson et al. | Jan 1988 | A |
4738666 | Fuqua | Apr 1988 | A |
4739762 | Palmaz | Apr 1988 | A |
4748666 | Fuqua | May 1988 | A |
4772266 | Groshong | Sep 1988 | A |
4790817 | Luther | Dec 1988 | A |
4798193 | Giesy et al. | Jan 1989 | A |
4846791 | Hattler et al. | Jul 1989 | A |
4865593 | Ogawa et al. | Sep 1989 | A |
4869717 | Adair | Sep 1989 | A |
4884573 | Wijay et al. | Dec 1989 | A |
4888000 | McQuilkin et al. | Dec 1989 | A |
4896669 | Bhate et al. | Jan 1990 | A |
4898581 | Jang et al. | Feb 1990 | A |
4899729 | Gill et al. | Feb 1990 | A |
4921479 | Grayzel | May 1990 | A |
4954126 | Wallsten | Sep 1990 | A |
4955895 | Sugiyama et al. | Sep 1990 | A |
4972827 | Kishi et al. | Nov 1990 | A |
4984564 | Yuen | Jan 1991 | A |
4986830 | Owens et al. | Jan 1991 | A |
5001488 | Ginsburg et al. | Apr 1991 | A |
5011488 | Ginsburg et al. | Apr 1991 | A |
5035686 | Crittenden et al. | Jul 1991 | A |
5045056 | Behl | Sep 1991 | A |
5057092 | Webster, Jr. | Oct 1991 | A |
5066285 | Lundquist et al. | Nov 1991 | A |
5073166 | Parks et al. | Dec 1991 | A |
5078736 | Behl | Jan 1992 | A |
5092839 | Kipperman | Mar 1992 | A |
5098393 | Amplatz et al. | Mar 1992 | A |
5100388 | Behl et al. | Mar 1992 | A |
5108413 | Moyers | Apr 1992 | A |
5108416 | Ryan et al. | Apr 1992 | A |
5112304 | Barlow et al. | May 1992 | A |
5112308 | Olsen et al. | May 1992 | A |
5116318 | Hillstead | May 1992 | A |
5122122 | Allgood | Jun 1992 | A |
5139511 | Gill et al. | Aug 1992 | A |
5147316 | Castillenti | Sep 1992 | A |
5158545 | Trudell | Oct 1992 | A |
5163903 | Crittenden et al. | Nov 1992 | A |
5176659 | Mancini | Jan 1993 | A |
5183464 | Dubrul | Feb 1993 | A |
5188602 | Nichols | Feb 1993 | A |
5201756 | Horzewski et al. | Apr 1993 | A |
5222938 | Behl | Jun 1993 | A |
5222971 | Willard et al. | Jun 1993 | A |
5234425 | Fogarty et al. | Aug 1993 | A |
5250025 | Sosnowski et al. | Oct 1993 | A |
5250033 | Evans et al. | Oct 1993 | A |
5256150 | Quiachone et al. | Oct 1993 | A |
5275611 | Behl | Jan 1994 | A |
5295994 | Bonutti | Mar 1994 | A |
5312360 | Behl | May 1994 | A |
5312417 | Wilk | May 1994 | A |
5316360 | Feikma | May 1994 | A |
5318588 | Horzewski et al. | Jun 1994 | A |
5320611 | Bonutti et al. | Jun 1994 | A |
5324261 | Amundson et al. | Jun 1994 | A |
5346503 | Chow et al. | Sep 1994 | A |
5380304 | Parker | Jan 1995 | A |
5392677 | Masterson et al. | Feb 1995 | A |
5395341 | Siater | Mar 1995 | A |
5395349 | Quiachon et al. | Mar 1995 | A |
5407430 | Peters | Apr 1995 | A |
5409469 | Schaerf | Apr 1995 | A |
5431676 | Dubrul et al. | Jul 1995 | A |
5433708 | Nichols et al. | Jul 1995 | A |
5447503 | Miller | Sep 1995 | A |
5454790 | Dubrul | Oct 1995 | A |
5460170 | Hammerslag | Oct 1995 | A |
5507767 | Maeda et al. | Apr 1996 | A |
5514091 | Yoon | May 1996 | A |
5514236 | Avellanet et al. | May 1996 | A |
5527336 | Rosenbluth | Jun 1996 | A |
5540658 | Evans et al. | Jul 1996 | A |
5542928 | Evans et al. | Aug 1996 | A |
5549635 | Solar | Aug 1996 | A |
5571089 | Crocker | Nov 1996 | A |
5573509 | Thornton | Nov 1996 | A |
5573517 | Bonutti et al. | Nov 1996 | A |
5573520 | Schwartz | Nov 1996 | A |
5657963 | Hincliffe et al. | Aug 1997 | A |
5662614 | Edoga | Sep 1997 | A |
5674240 | Bonutti et al. | Oct 1997 | A |
5674857 | Anderson et al. | Oct 1997 | A |
5700253 | Parker | Dec 1997 | A |
5702373 | Samson | Dec 1997 | A |
5709713 | Evans et al. | Jan 1998 | A |
5713867 | Morris | Feb 1998 | A |
5738667 | Solar | Apr 1998 | A |
5766203 | Imran et al. | Jun 1998 | A |
5776141 | Klein et al. | Jul 1998 | A |
5810776 | Bacich et al. | Sep 1998 | A |
5817100 | Igaki | Oct 1998 | A |
5846251 | Hart | Dec 1998 | A |
5868779 | Ruiz | Feb 1999 | A |
5869719 | Tsukernik | Feb 1999 | A |
5885217 | Gisselberg et al. | Mar 1999 | A |
5888196 | Bonutti | Mar 1999 | A |
5897557 | Chin et al. | Apr 1999 | A |
5902282 | Balbierz | May 1999 | A |
5908435 | Samuels | Jun 1999 | A |
5916145 | Chu et al. | Jul 1999 | A |
5922019 | Hankh et al. | Jul 1999 | A |
5961499 | Bonutti et al. | Oct 1999 | A |
5964730 | Williams et al. | Oct 1999 | A |
5971938 | Hart et al. | Oct 1999 | A |
5997508 | Lunn et al. | Dec 1999 | A |
6030364 | Durgin et al. | Feb 2000 | A |
6056718 | Funderburk et al. | May 2000 | A |
6063056 | Engelberg | May 2000 | A |
6080174 | Dubrul et al. | Jun 2000 | A |
6090072 | Kratoska et al. | Jul 2000 | A |
6120480 | Zhang et al. | Sep 2000 | A |
6123689 | To et al. | Sep 2000 | A |
6168579 | Tsugita | Jan 2001 | B1 |
6183443 | Kratoska et al. | Feb 2001 | B1 |
6187000 | Davison et al. | Feb 2001 | B1 |
6197016 | Fourkas et al. | Mar 2001 | B1 |
6228052 | Pohndorf | May 2001 | B1 |
6248116 | Chevillon et al. | Jun 2001 | B1 |
6280452 | Mears | Aug 2001 | B1 |
6293909 | Chu et al. | Sep 2001 | B1 |
6312443 | Stone | Nov 2001 | B1 |
6358238 | Sherry | Mar 2002 | B1 |
6443979 | Stalker et al. | Sep 2002 | B1 |
6447540 | Fontaine et al. | Sep 2002 | B1 |
6471684 | Dulak et al. | Oct 2002 | B2 |
6494860 | Rocamora et al. | Dec 2002 | B2 |
6494893 | Dubrul et al. | Dec 2002 | B2 |
6517551 | Driskill | Feb 2003 | B1 |
6524268 | Hayner et al. | Feb 2003 | B2 |
6524320 | DiPoto | Feb 2003 | B2 |
6530902 | Jonkman | Mar 2003 | B1 |
6582395 | Burkett et al. | Jun 2003 | B1 |
6613038 | Bonnutti et al. | Sep 2003 | B2 |
6613062 | Leckrone et al. | Sep 2003 | B1 |
6616678 | Nishtala et al. | Sep 2003 | B2 |
6638268 | Niazi | Oct 2003 | B2 |
6679902 | Boyle et al. | Jan 2004 | B1 |
6692462 | Mackenzie et al. | Feb 2004 | B2 |
6706017 | Dulguerov | Mar 2004 | B1 |
6808520 | Fourkas | Oct 2004 | B1 |
6827683 | Otawara | Dec 2004 | B2 |
6951555 | Suresh et al. | Oct 2005 | B1 |
7033369 | Davison et al. | Apr 2006 | B2 |
7056319 | Aliperti et al. | Jun 2006 | B2 |
7135015 | Dulak et al. | Nov 2006 | B2 |
7309334 | Von Hoffman | Dec 2007 | B2 |
7316677 | Dulak et al. | Jan 2008 | B1 |
7329268 | Van Nguyen et al. | Feb 2008 | B2 |
7457661 | Doty | Nov 2008 | B2 |
20010012950 | Nishtala et al. | Aug 2001 | A1 |
20010037126 | Stack et al. | Nov 2001 | A1 |
20020009535 | Michal et al. | Jan 2002 | A1 |
20020010440 | Segesser | Jan 2002 | A1 |
20020010476 | Mulholland et al. | Jan 2002 | A1 |
20020077653 | Hudson et al. | Jun 2002 | A1 |
20020099431 | Armstrong et al. | Jul 2002 | A1 |
20020161377 | Rabkin | Oct 2002 | A1 |
20030050600 | Ressemann et al. | Mar 2003 | A1 |
20030065353 | Horzewski et al. | Apr 2003 | A1 |
20030135156 | Bencini et al. | Jul 2003 | A1 |
20030195551 | Davison et al. | Oct 2003 | A1 |
20030212384 | Hayeden | Nov 2003 | A1 |
20030216770 | Persidsky et al. | Nov 2003 | A1 |
20030233115 | Eversull | Dec 2003 | A1 |
20040006344 | Nguyen et al. | Jan 2004 | A1 |
20040073286 | Armstrong et al. | Apr 2004 | A1 |
20040087968 | Core | May 2004 | A1 |
20040181273 | Brasington et al. | Sep 2004 | A1 |
20040220549 | Dittman et al. | Nov 2004 | A1 |
20040236346 | Parker | Nov 2004 | A1 |
20050043780 | Gifford et al. | Feb 2005 | A1 |
20050085842 | Eversull et al. | Apr 2005 | A1 |
20050124937 | Kick et al. | Jun 2005 | A1 |
20050125021 | Nance et al. | Jun 2005 | A1 |
20050149105 | Leeflang et al. | Jul 2005 | A1 |
20050222576 | Kick et al. | Oct 2005 | A1 |
20060036276 | Nguyen et al. | Feb 2006 | A1 |
20060052750 | Lenker et al. | Mar 2006 | A1 |
20060142795 | Nguyen et al. | Jun 2006 | A1 |
20060200188 | Nance et al. | Sep 2006 | A1 |
20060200189 | Nance et al. | Sep 2006 | A1 |
20060247602 | Dulak et al. | Nov 2006 | A1 |
20070112335 | Dulak et al. | May 2007 | A1 |
Number | Date | Country |
---|---|---|
0177177 | Apr 1986 | EP |
0249456 | Dec 1987 | EP |
024945611 | Dec 1987 | EP |
0385920 | Sep 1990 | EP |
0206553 | Jan 1991 | EP |
0421650 | Apr 1991 | EP |
0546766 | Jun 1993 | EP |
WO1992019312 | Nov 1992 | WO |
WO1995030374 | Nov 1995 | WO |
WO1999016499 | Apr 1999 | WO |
WO1999017665 | Apr 1999 | WO |
WO2003090834 | Nov 2003 | WO |
Entry |
---|
United States Patent and Trademark Office, Notice of Allowance dated Sep. 16, 2015 in U.S. Appl. No. 10/728,728, 9 pages. |
United States Patent and Trademark Office, Examiner's Answer dated Jun. 21, 2012 in U.S. Appl. No. 10/y28,728, 13 pages. |
United States Patent and Trademark Office, Final Office Action dated Jul. 22, 2011 in U.S. Appl. No. 10/728,728, 13 pages. |
European Patent Office, Communication in European Application No. 04813043.9 filed on Dec. 3, 2004. |
United States Patent and Trademark Office, Office Action dated Oct. 29, 2010 in U.S. Appl. No. 10/728,728, 14 pages. |
United States Patent and Trademark Office, Final Office Action dated Mar. 22, 2010 in U.S. Appl. No. 10/728,728, 17 pages. |
United States Patent and Trademark Office, Office Action dated Mar. 19, 2010 in U.S. Appl. No. 11/415,764. |
United States Patent and Trademark Office, Response dated Oct. 16, 2009 to Non-final Rejection in U.S. Appl. No. 11/884,017. |
United States Patent and Trademark Office, Response dated Sep. 15, 2009 to Office Action in U.S. Appl. No. 11/223,897. |
United States Patent and Trademark Office, Office Action dated Jul. 23, 2009 in U.S. Appl. No. 10/728,728, 15 pages. |
United States Patent and Trademark Office, Office Action dated Jul. 22, 2009 in U.S. Appl. No. 11/415,659. |
United States Patent and Trademark Office, Final Office Action dated Jun. 30, 2009 in U.S. Appl. No. 11/415,764. |
European Patent Office, Communication dated May 25, 2009 in European Patent Application No. 04813043.9. |
United States Patent and Trademark Office, Response dated May 12, 2009 to Final Office Action in U.S. Appl. No. 11/223,897. |
United States Patent and Trademark Office, Response dated May 11, 2009 to Final Office Action in U.S. Appl. No. 11/415,659. |
United States Patent and Trademark Office, Office Action dated Apr. 17, 2009 in U.S. Appl. No. 11/884,017. |
United States Patent and Trademark Office, Final Office Action dated Apr. 17, 2009 in U.S. Appl. No. 11/223,897. |
United States Patent and Trademark Office, Final Office Action dated Apr. 6, 2009 in U.S. Appl. No. 11/415,659. |
United States Patent and Trademark Office, Response dated Mar. 2, 2009 in U.S. Appl. No. 11/884,017. |
United States Patent and Trademark Office, Final Office Action dated Feb. 19, 2009 in U.S. Appl. No. 10/728,728, 10 pages. |
United States Patent and Trademark Office, Restriction Requirement dated Feb. 5, 2009 in U.S. Appl. No. 11/884,017. |
United States Patent and Trademark Office, Response dated Feb. 3, 2009 to Office Action in U.S. Appl. No. 11/223,897. |
European Patent Office, Response dated Jan. 15, 2009 to Jul. 14, 2008 Communication in European Application No. 05794899.4. |
United States Patent and Trademark Office, Response dated Dec. 12, 2008 to Office Action in U.S. Appl. No. 11/415,764. |
United States Patent and Trademark Office, Response dated Nov. 19, 2008 to Office Action in U.S. Appl. No. 11/415,659. |
United States Patent and Trademark Office, Office Action dated Oct. 3, 2008 in U.S. Appl. No. 11/223,897. |
European Patent Office, Response dated Aug. 11, 2008 to European Patent Office Communication dated Jan. 30, 2008 in European Patent Application No. 04813043.9. |
European Patent Office, Communication dated Jul. 14, 2008 in European Patent Application No. 05794899.4 |
United States Patent and Trademark Office, Office Action dated Jun. 13, 2008 in U.S. Appl. No. 11/415,764. |
United States Patent and Trademark Office, Office Action dated May 28, 2009 in U.S. Appl. No. 10/728,728, 20 pages. |
United States Patent and Trademark Office, Office Action dated May 20, 2008 in U.S. Appl. No. 11/415,659. |
United States Patent and Trademark Office, Response dated Feb. 20, 2008 to Final Office Action in U.S. Appl. No. 11/415,659. |
United States Patent and Trademark Office, Response dated Feb. 20, 2008 to Office Action in U.S. Appl. No. 11/415,764. |
European Patent Office, Communication dated Jan. 30, 2008 in European Patent Application No. 04813043.9. |
United States Patent and Trademark Office, Advisory Action dated Nov. 16, 2007 in U.S. Appl. No. 11/415,659. |
United States Patent and Trademark Office, Response dated Nov. 7, 2007 to Final Office Action in U.S. Appl. No. 11/415,659. |
United States Patent and Trademark Office, Office Action dated Oct. 18, 2007 in U.S. Appl. No. 10/728,728, 9 pages. |
European Patent Office, Examination Report dated Aug. 21, 2007 in European Patent Application No. 05794899.4. |
United States Patent and Trademark Office, Final Office Action dated Aug. 20, 2007 in U.S. Appl. No. 11/415,659. |
United States Patent and Trademark Office, Office Action dated Aug. 20, 2007 in U.S. Appl. No. 11/415,764. |
United States Patent and Trademark Office, Response dated Jun. 11, 2007 to Office Action in U.S. Appl. No. 11/415,659. |
United States Patent and Trademark Office, Response dated Jun. 8, 2007 to Office Action in U.S. Appl. No. 11/415,764. |
United States Patent and Trademark Office, Notice of Allowance dated May 1, 2007 in U.S. Appl. No. 10/728,728, 11 pages. |
WIPO, U.S. International Search Authority, International Search Report dated Apr. 3, 2007 in International Patent Application No. PCT/US2005/031958. |
United States Patent and Trademark Office, Office Action dated Jan. 10, 2007 in U.S. Appl. No. 11/415,659. |
United States Patent and Trademark Office, Office Action dated Jan. 8, 2007 in U.S. Appl. No. 11/415,764. |
United States Patent and Trademark Office, Office Action dated Sep. 13, 2006 in U.S. Appl. No. 10/728,728, 14 pages. |
United States Patent and Trademark Office, prosecution history in U.S. Patent Publication No. 2006/0200188 published Sep. 7, 2006. |
United States Patent and Trademark Office, prosecution history in U.S. Patent Publication No. 2006/0200189 published Sep. 7, 2006. |
WIPO, International Preliminary Examining Authority (U.S. Patent and Trademark Office), International Preliminary Report on Patentability dated Jun. 15, 2006 in International Patent Application No. PCT/US2004/040651. |
WIPO, U.S. International Search Authority, International Search Report dated Jun. 7, 2006 in International Patent Application No. PCT/US2004/040651. |
WIPO, U.S. International Search Authority, International Search Report dated Oct. 28, 2005 in International Patent Application No. PCT/US2004/040651. |
United States Patent and Trademark Office, prosecution history in U.S. Patent Publication No. 2005/0125021 published Jun. 9, 2005. |
United States Patent and Trademark Office, Office Action dated Jun. 30, 2009 in U.S. Appl. No. 11/223,897. |
Number | Date | Country | |
---|---|---|---|
20160135840 A1 | May 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10728728 | Dec 2003 | US |
Child | 15006025 | US |